Effect of allium cepa-allantoin-pentaglycan gel on skin hypertrophic scars: clinical and video-capillaroscopic results of an open-label, controlled, nonrandomized clinical trial.
BACKGROUND
Hypertrophic scar formation is a process in which prolonged angiogenesis sustained by vascular endothelial growth factor cutaneous expression plays an important role.


OBJECTIVE
This in vivo study was conducted to evaluate the clinical effect of a topical gel containing onion extract, allantoin, and pentaglycan on hypertrophic scars and keloids.


METHODS
Thirty people with hypertrophic scars or keloids were examined. Fifteen patients received a topical application of a gel containing allium cepa, allantoin, and pentaglycan twice a day for 24 weeks, the remaining 15 patients received no topical treatments. A clinical evaluation and an intravital videocapillaroscopy were performed on every patient at baseline (T0) and 24 weeks (T24) after the treatment.


RESULTS
Only the patients who received the topical treatment showed a significant reduction in neoangiogenetic features, demonstrated through an improvement of erythema and all videocapillaroscopic markers of neoangiogenesis. These changes induced by therapy led to a general improvement of the lesions.


CONCLUSIONS
Topical applications of a gel containing allium cepa, pentaglycan, and allantoin twice a day for 24 weeks seems to be useful in reducing neoangiogenesis in hypertrophic scars and keloids, resulting in clinical improvement of skin lesions. The authors have indicated no significant interest with commercial supporters.
Campanati
Anna
A
Dermatology Clinic, Department of Clinical Medicine and Biotechnology, Universitá Politecnica delle Marche, Ancona, Italy. nati@univpm.it
Savelli
Andrea
A
Sandroni
Lucia
L
Marconi
Barbara
B
Giuliano
Angela
A
Giuliodori
Katia
K
Ganzetti
Giulia
G
Offidani
Annamaria
A
D000328:Adult; D000481:Allantoin / Q000627:therapeutic use*; D017439:Cicatrix, Hypertrophic / Q000188:drug therapy* / Q000473:pathology*; D004359:Drug Therapy, Combination; D005260:Female; D005782:Gels; D006801:Humans; D007627:Keloid / Q000188:drug therapy* / Q000473:pathology*; D008297:Male; D020678:Microscopic Angioscopy; D019697:Onions; D008517:Phytotherapy; D010936:Plant Extracts / Q000627:therapeutic use*; D011134:Polysaccharides / Q000627:therapeutic use*; D014741:Video Recording
D005782:Gels; D010936:Plant Extracts; D011134:Polysaccharides; D000481:Allantoin